Form 4: IN8BIO Director Alan S. Roemer Reports Changes in Beneficial Ownership After Warrant Amendments

Director Alan S. Roemer reports changes in beneficial ownership of IN8BIO, INC. stock and warrants due to amendments of warrant terms.

Summary

• On April 27, 2025, and April 30, 2025, Alan S. Roemer, a director of IN8BIO, INC., engaged in transactions involving the company's common stock and warrants.
• These transactions primarily involved amendments to outstanding warrants, which resulted in the deemed cancellation of old warrants and the grant of replacement warrants.
• The exercise price of certain Series A and Series B warrants was reduced from $0.45 and $1.50 per share, respectively, to $0.1844 per share, with some expiration dates amended to May 2, 2025.
• Roemer acquired 102,459 shares of common stock and disposed of 102,459 Series A warrants on April 30, 2025, through the exercise of warrants at a price of $0.1844.
• Additionally, Roemer acquired 11,000 shares of common stock and disposed of 11,000 Series B warrants on April 30, 2025, also through warrant exercises at $0.1844.
• Following these transactions, Roemer directly owns 398,489 shares of IN8BIO common stock and various Series A and B warrants.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about changes in ownership.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies. The warrant amendments and subsequent exercises could be part of a broader strategy to manage the company's capital structure or incentivize management.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
• The details disclosed in this filing are consistent with the level of information typically provided in such filings.
• Warrant amendments and exercises are common financial maneuvers used by companies to manage their capital structure, similar to practices observed in comparable biotech firms.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of management's confidence in the company.
• The warrant exercises will result in the issuance of new shares, which could potentially dilute existing shareholders' ownership.

Key Dates

Keywords

IN8BIO, Alan S. Roemer, beneficial ownership, warrants, amendment, common stock, director, exercise price, expiration date